Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABEONA THERAPEUTICS INC.ABEO · Entity 5808 | Director | September 26, 2022 | September 28, 2022 |
| AETERNUM HEALTH, INC.AETN · Entity 7865 | Director · CEO · 10% owner | June 30, 2026 | July 15, 2026 |
| ASP Isotopes Inc.ASPI · Entity 5371 | Director · Chairman and CEO | September 02, 2026 | September 05, 2026 |
| Healthtech Solutions, Inc./UTHLTT · Entity 121972 | Director | November 10, 2021 | November 30, 2022 |
| Illumination Acquisition Corp. IILLU · Entity 5913 | Director | February 26, 2026 | February 26, 2026 |
| POLARITYTE, INC.PTE · Entity 117561 | Chief Financial Officer | March 31, 2020 | April 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABEONA THERAPEUTICS INC.
Report date September 26, 2022 · Filed September 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,907 |
Reported balance
After 2022-09-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-09-26 · Grant · Acquired 13,400 · Balance 16,907 F1: All of the restricted stock will vest on September 26, 2023. F2: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the restricted stock will vest on September 26, 2023.
F2: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split.
AETERNUM HEALTH, INC.
Report date June 30, 2026 · Filed July 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,000,000 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 49,000,000 F1: The shares were issued in connection with a reverse merger agreement between Aeternum Health, LLC and Shorepower Technologies, Inc. |
| Preferred StockSEC Table I · non-derivative | Direct | 2,000,000 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,000,000 F1: The shares were issued in connection with a reverse merger agreement between Aeternum Health, LLC and Shorepower Technologies, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued in connection with a reverse merger agreement between Aeternum Health, LLC and Shorepower Technologies, Inc.
ASP Isotopes Inc.
Report date September 02, 2026 · Filed September 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,328,570 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-02 · Sale · Disposed 83,758 · Balance 9,496,087 F1: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.96, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2026-09-03 · Sale · Disposed 83,758 · Balance 9,412,329 F1: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.875 to $3.98, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-09-04 · Sale · Disposed 83,759 · Balance 9,328,570 F1: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.925 to $4.26, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.96, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.875 to $3.98, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.925 to $4.26, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Healthtech Solutions, Inc./UT
Report date November 10, 2021 · Filed November 30, 2022 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,666,667 |
Last balance in matching sequence
After 2022-11-22 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-11-10 · Grant · Acquired 1,500,000 · Balance 1,500,000 F1: The award was for no consideration other than services as a member of the Board of Directors. Row 2 · 2022-06-30 · Exercise / conversion · Acquired 166,667 · Balance 1,666,667 F2: The award was for no consideration other than services as a member of the Board of Directors. Row 3 · 2022-11-22 · Grant · Acquired 1,000,000 · Balance 2,666,667 F3: The award was for no consideration other than services as a member of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The award was for no consideration other than services as a member of the Board of Directors.
F2: The award was for no consideration other than services as a member of the Board of Directors.
F3: The award was for no consideration other than services as a member of the Board of Directors.
Illumination Acquisition Corp. I
Report date February 26, 2026 · Filed February 26, 2026
This filing explicitly reported no securities owned.
POLARITYTE, INC.
Report date March 31, 2020 · Filed April 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 415,953 |
Reported balance
After 2020-03-31 transaction · row 1
1 source rowRow 1 · 2020-03-31 · Sale · Disposed 23,158 · Balance 415,953 F1: The reported sale was effectuated pursuant to a 10b5-1 trading plan adopted by the reporting person on September 12, 2019, as amended November 19, 2019. The sale is intended to cover withholding taxes resulting from vesting of restricted stock units that were previously reported on Table I. F2: The reported price is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.00 to $1.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price that was included in the calculation of the weighted average price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported sale was effectuated pursuant to a 10b5-1 trading plan adopted by the reporting person on September 12, 2019, as amended November 19, 2019. The sale is intended to cover withholding taxes resulting from vesting of restricted stock units that were previously reported on Table I.
F2: The reported price is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.00 to $1.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price that was included in the calculation of the weighted average price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 5, 2026 01:30 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 83,759 | $4.10 | $343,411.90 |
DisclosureSEC source: 0001477932-26-005430 · form4.xml · nonDerivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,328,570 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.925 to $4.26, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 03, 2026 Filed Sep 5, 2026 01:30 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 83,758 | $3.92 | $328,331.36 |
DisclosureSEC source: 0001477932-26-005430 · form4.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,412,329 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.875 to $3.98, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2026 Filed Sep 5, 2026 01:30 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 83,758 | $3.91 | $327,493.78 |
DisclosureSEC source: 0001477932-26-005430 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,496,087 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.96, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 83,759 | $7.76 | $649,969.84 |
DisclosureSEC source: 0001477932-26-003633 · form4.xml · nonDerivative · entry 4 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,579,845 F2 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.53 to $8.13, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 83,758 | $8.29 | $694,353.82 |
DisclosureSEC source: 0001477932-26-003633 · form4.xml · nonDerivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,663,424 F2 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.81 to $8.52, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 83,758 | $7.88 | $660,013.04 |
DisclosureSEC source: 0001477932-26-003633 · form4.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,747,182 F2 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 30, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.49 to $8.14, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 28, 2026 Filed Jun 4, 2026 01:45 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 2,233,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-26-003633 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,830,940 F1 · date: This award of common stock was issued to the reporting person pursuant to his Employment Agreement dated October 4, 2021, as amended on December 20, 2022 and April 5, 2024, and shall vest (subject to compliance with applicable vesting conditions) in four equal installments over a one-year period beginning on March 1, 2026. F1 · price: This award of common stock was issued to the reporting person pursuant to his Employment Agreement dated October 4, 2021, as amended on December 20, 2022 and April 5, 2024, and shall vest (subject to compliance with applicable vesting conditions) in four equal installments over a one-year period beginning on March 1, 2026. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 02:50 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 162,153 | $5.44 | $881,463.71 |
DisclosureSEC source: 0001477932-26-001127 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,597,385 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on June 9, 2025 to cover tax withholding obligations in connection with the quarterly vesting of a restricted stock award. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.57, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| December 01, 2025 Filed Dec 4, 2025 02:42 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 162,153 | $5.75 | $932,866.21 |
DisclosureSEC source: 0001477932-25-008769 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,759,538 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on June 9, 2025 to cover tax withholding obligations in connection with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.565 to $5.9565, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| November 25, 2025 Filed Nov 29, 2025 02:41 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 50,000 | $5.77 | $288,450.00 |
DisclosureSEC source: 0001477932-25-008681 · form4.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director · Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,921,691 F3 · kind: Represents sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on December 13, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.54 to $6.015, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| November 17, 2025 Filed Nov 29, 2025 02:41 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 112,500 | $7.51 | $844,537.50 |
DisclosureSEC source: 0001477932-25-008681 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,971,691 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on June 9, 2025 to cover tax withholding obligations in connection with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.215 to $7.85, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · derivative · entry 8 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2032-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: These options vested in thirty-six equal installments beginning on the last day of month after the option's grant date. The option was granted on June 10, 2022. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 216,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · derivative · entry 7 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 216,000 shares Expires 2032-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options vested in a single installment 12 months after the grant date. The option was granted on April 4, 2022. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 81,077 | $8.39 | $680,122.52 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · nonDerivative · entry 6 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,084,191 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on June 9, 2025 to cover tax withholding obligations in connection with the vesting of restricted stock awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.135 to $8.575, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Tax withholdingCommon Stock | 234,466 | $8.53 | $1,999,994.98 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · nonDerivative · entry 5 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,165,268 F3 · kind: Represents shares withheld by the Company in connection with net share settlement to satisfy the exercise price associated with the reporting person's exercise of employee stock options. No shares were sold by the reporting person to satisfy the exercise price or any tax liability. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Exercise / conversionCommon Stock | 1,000,000 | $2.00 | $2,000,000.00 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · nonDerivative · entry 4 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,399,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Tax withholdingCommon Stock | 50,644 | $8.53 | $431,993.32 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · nonDerivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,399,734 F3 · kind: Represents shares withheld by the Company in connection with net share settlement to satisfy the exercise price associated with the reporting person's exercise of employee stock options. No shares were sold by the reporting person to satisfy the exercise price or any tax liability. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | Exercise / conversionCommon Stock | 216,000 | $2.00 | $432,000.00 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,450,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2025 Filed Sep 11, 2025 01:00 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 81,076 | $8.53 | $691,408.02 |
DisclosureSEC source: 0001477932-25-006619 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,234,378 F1 · kind: Represents "sell to cover" sales effected pursuant to a Rule 10b5-1 trading plan adopted by the filing person on June 9, 2025 to cover tax withholding obligations in connection with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.135 to $8.575, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| April 17, 2025 Filed Apr 17, 2025 23:57 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 316,666 | $5.62 | $1,780,074.59 |
DisclosureSEC source: 0001477932-25-002833 · form4.xml · nonDerivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,315,454 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Paul Mann dated December 13, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $6.02, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 4. Read SEC document |
| April 16, 2025 Filed Apr 17, 2025 23:57 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 316,667 | $5.45 | $1,724,378.48 |
DisclosureSEC source: 0001477932-25-002833 · form4.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,632,120 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Paul Mann dated December 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.26 to $5.70, inclusive. The reporting person undertakes to provide the Company, any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 3. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 23:57 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | SaleCommon Stock | 316,667 | $5.75 | $1,821,943.58 |
DisclosureSEC source: 0001477932-25-002833 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,948,787 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Paul Mann dated December 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.48 to $6.70, inclusive. The reporting person undertakes to provide ASP Isotopes Inc. (the "Company"), any stockholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote 2. Read SEC document |
| April 14, 2025 Filed Apr 15, 2025 12:42 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 1,441,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-25-002716 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,265,454 F1 · date: This award of common stock was issued to the reporting person pursuant to his Employment Agreement dated October 4, 2021, as amended on December 20, 2022, and shall vest (subject to compliance with applicable vesting conditions) in four equal installments over a one-year period beginning on March 1, 2025. F1 · price: This award of common stock was issued to the reporting person pursuant to his Employment Agreement dated October 4, 2021, as amended on December 20, 2022, and shall vest (subject to compliance with applicable vesting conditions) in four equal installments over a one-year period beginning on March 1, 2025. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 22:37 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 978,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-005649 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,824,093 F1 · date: This award of common stock was issued to the reporting person pursuant to his Employment Agreement dated October 4, 2021, as amended on December 20, 2022, and shall vest (subject to compliance with applicable vesting conditions) in four equal installments over a one-year period beginning on March 1, 2024. F1 · price: This award of common stock was issued to the reporting person pursuant to his Employment Agreement dated October 4, 2021, as amended on December 20, 2022, and shall vest (subject to compliance with applicable vesting conditions) in four equal installments over a one-year period beginning on March 1, 2024. Read SEC document |
| July 15, 2024 Filed Jul 15, 2024 14:33 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | PurchaseCommon Stock | 39,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001477932-24-004208 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,845,627 F1 · date: Represents shares of Common Stock purchased by the reporting person at the public offering price of $2.50 per share in connection with the issuer's underwritten public offering of Common Stock, which closed on July 15, 2024. F1 · price: Represents shares of Common Stock purchased by the reporting person at the public offering price of $2.50 per share in connection with the issuer's underwritten public offering of Common Stock, which closed on July 15, 2024. Read SEC document |
| March 01, 2023 Filed Mar 8, 2023 21:05 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 718,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-001369 · form4.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,805,643 F1 · deemedExecutionDate: On March 1, 2023, the Company granted 718,143 shares of the Company's restricted common stock to Paul Mann pursuant to an amended Employment Agreement dated December 20, 2022. 179,536 shares of the common stock vest on each June 1, 2023, September 1, 2023, December 1, 2023 and March 1, 2024. Read SEC document |
| December 30, 2022 Filed Feb 17, 2023 17:14 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-001110 · primary_doc.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,087,500 F1 · deemedExecutionDate: On December 30, 2022, the Company issued 1,000,000 shares of the Company's restricted common stock to Paul Mann as a bonus for services provided during the fiscal year ended December 31, 2022. Read SEC document |
| November 22, 2022 Filed Nov 30, 2022 21:47 UTC Amendment | Healthtech Solutions, Inc./UT HLTT · Entity 121972 | GrantCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001290929-22-000003 · primary_doc.xml · nonDerivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666,667 F3 · price: The award was for no consideration other than services as a member of the Board of Directors. Read SEC document |
| November 22, 2022 Filed Nov 30, 2022 21:31 UTC | Healthtech Solutions, Inc./UT HLTT · Entity 121972 | GrantCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001290929-22-000002 · primary_doc.xml · nonDerivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 F3 · price: The award was for no consideration other than services as a member of the Board of Directors. Read SEC document |
| November 15, 2022 Filed Nov 15, 2022 13:19 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-072582 · ownership.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,087,500 F1 · deemedExecutionDate: This special one-time equity award of 1,000,000 restricted shares was contingent upon the completion of our IPO. Mr. Mann will receive 250,000 restricted shares of our common stock on November 15, 2023, 250,000 restricted shares of our common stock on November 15, 2024, 250,000 restricted shares of our common stock on November 15, 2025, and 250,000 shares of our restricted common stock on November 15, 2026. Read SEC document |
| November 15, 2022 Filed Nov 15, 2022 13:19 UTC | ASP Isotopes Inc. ASPI · Entity 5371 | GrantCommon Stock | 37,500 | $4.00 | $150,000.00 |
DisclosureSEC source: 0001213900-22-072582 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,087,500 Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:34 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027045 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,907 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| June 30, 2022 Filed Nov 30, 2022 21:47 UTC Amendment | Healthtech Solutions, Inc./UT HLTT · Entity 121972 | Exercise / conversionCommon Stock | 166,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001290929-22-000003 · primary_doc.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,666,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The award was for no consideration other than services as a member of the Board of Directors. Read SEC document |
| June 30, 2022 Filed Nov 30, 2022 21:31 UTC | Healthtech Solutions, Inc./UT HLTT · Entity 121972 | Exercise / conversionCommon Stock | 500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001290929-22-000002 · primary_doc.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The award was for no consideration other than services as a member of the Board of Directors. Read SEC document |
| November 10, 2021 Filed Nov 30, 2022 21:47 UTC Amendment | Healthtech Solutions, Inc./UT HLTT · Entity 121972 | GrantCommon Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001290929-22-000003 · primary_doc.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 F1 · price: The award was for no consideration other than services as a member of the Board of Directors. Read SEC document |
| November 10, 2021 Filed Nov 30, 2022 21:31 UTC | Healthtech Solutions, Inc./UT HLTT · Entity 121972 | GrantCommon Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001290929-22-000002 · primary_doc.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 F1 · price: The award was for no consideration other than services as a member of the Board of Directors. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:49 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 49,084 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-21-013126 · ownership.xml · derivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,084 Underlying: Common Stock · 49,084 shares Expires 2031-05-25 F2 · derivative.exercise_date: All of the stock options will vest on November 25, 2021. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:49 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 38,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013126 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,590 F1 · shares: All of the restricted stock will vest on November 25, 2021. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:14 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,566 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001493152-21-004598 · ownership.xml · derivative · entry 3 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,566 shares Expires 2030-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:14 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 45,566 | $2.38 | $108,501.76 |
DisclosureSEC source: 0001493152-21-004598 · ownership.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.34 to $2.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:14 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Exercise / conversionCommon Stock | 45,566 | $1.28 | $58,324.48 |
DisclosureSEC source: 0001493152-21-004598 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 132,664 | $2.34 | $310,168.43 |
DisclosureSEC source: 0001493152-21-004408 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.19 to $2.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.19 to $2.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 00:07 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 30,488 | $1.54 | $46,890.54 |
DisclosureSEC source: 0001493152-21-000247 · ownership.xml · nonDerivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,664 F2 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.50 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 00:07 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerCommon Stock | 609,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-000247 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,152 F1 · kind: Represents unvested shares of restricted common stock granted to the reporting person on October 8, 2020 in connection with the formation of a special committee of the Issuer's board of directors as reported on Form 8-K on October 6, 2020. These shares were scheduled to vest in monthly installments only while the special committee was operational and the reporting person was providing service to the special committee; the special committee was dissolved on December 31, 2020. The reporting person continues to serve on the Issuer's board of directors. Read SEC document |
| December 18, 2020 Filed Dec 21, 2020 23:16 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 17,079 | $1.59 | $27,099.25 |
DisclosureSEC source: 0001493152-20-024068 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,907 F1 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.575 to $1.595, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 02, 2020 Filed Dec 2, 2020 21:25 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 30,488 | $1.49 | $45,369.19 |
DisclosureSEC source: 0001493152-20-022826 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,986 F1 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.46 to $1.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 45,566 | Not disclosed Strike: $3.03 | Not disclosed |
DisclosureSEC source: 0001493152-20-022150 · ownership.xml · derivative · entry 2 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,566 shares Expires 2030-06-17 F2 · price: The options granted on June 17, 2020 have been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 100% on December 17, 2020. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 45,566 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022150 · ownership.xml · derivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,566 Underlying: Common Stock · 45,566 shares Expires 2030-06-17 F2 · price: The options granted on June 17, 2020 have been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 100% on December 17, 2020. Read SEC document |
| November 02, 2020 Filed Nov 6, 2020 21:54 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 30,488 | $1.04 | $31,588.62 |
DisclosureSEC source: 0001493152-20-020708 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 820,474 F1 · kind: The sales reported in this Form 4 were to cover tax obligations associated with vested restricted stock awards and were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.03 to $1.055, inclusive. The reporting person undertakes to provide to the Issuer, any security holder, or the Staff of the SEC, upon request, full information regarding the number of shares disposed at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 22:29 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 813,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-019386 · ownership.xml · nonDerivative · entry 1 Mann Paul Elliot · CIK 0001744816 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,962 F1 · shares: The restricted stock will vest in 12 equal monthly installments beginning on October 31, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.